Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERECA: Ilixadencel + Sunitinib in Metastatic Renal Cell Carcinoma
NCT02432846Phase 2Completed
- Sponsor
- Mendus
- Start
- Apr 2015
- Primary completion
- Jan 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 9
01
Overview
A Phase 2 trial of ilixadencel in metastatic renal cell carcinoma (mRCC), sponsored by Mendus. Started Apr 2015; status: completed.
02
Drugs
ilixadencel
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02432846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432846.